Company ProfilePremium

Alkem Laboratories Limited

Company Profile Analysis

Tickers: ALKEM.NS, 539523.BO

ESOMAR 23 Corporate BadgeISO Certifications Badge
Alkem Laboratories Limited - Company showcase

Year Founded & Workforce

1973

21,057 Employees

Alkem Laboratories Limited logo

Alkem Laboratories Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Alkem Laboratories Limited Overview

Alkem Laboratories is India's sixth-largest pharmaceutical company by value in the Indian Pharmaceutical Market (IQVIA SSA MAT March 2026) and third-largest by prescriptions (SMSRC MAT February 2026), with a five-decade franchise built on acute-care mega-brands — most notably Clavam (amoxicillin-clavulanate), the PAN pantoprazole family (the second-largest brand family in the IPM), Taxim and A to Z. It has led the anti-infectives therapy area in India for more than 15 years. Roughly two-thirds of FY26 revenue of INR 147.1 bn came from India, with the balance from a US generics business (Ascend Laboratories, ~20% of sales) and a fast-growing non-US international portfolio (~12%). Under a promoter-family governance model, Alkem is repositioning toward chronic therapies (anti-diabetics including semaglutide, neuro, derma, cardiac), biosimilars and CDMO via Enzene Biosciences, and medical devices via Alkem MedTech — the last now anchored by the July 2026 acquisition of a controlling stake in Swiss structural-heart device maker Occlutech. It carries a net-cash balance sheet (INR 57.6 bn at 30 June 2026).


Company's own description

In its Q1 FY27 press release (14 August 2026), Alkem describes itself as the sixth-largest pharmaceutical company in the Indian market with more than 50 years of heritage, a dominant position in anti-infectives, gastrointestinal, pain management and supplements, and a growing chronic portfolio spanning diabetes, neurology, dermatology and urology. It states that it operates 20 manufacturing facilities and R&D centres producing generic formulations, active pharmaceutical ingredients (APIs) and biosimilars, and that outside India it has a meaningful presence in the US, Latin America, Australia, Europe and several Asian markets. Its corporate purpose line is "Inspiring Healthier Lives". For statutory segment reporting the company reports a single business segment — pharmaceuticals — with geographic disclosure of India and international (Morningstar profile; company filings).

Independent characterization

Alkem is best characterized as a domestic branded-generics franchise with three option-value adjacencies bolted onto a cash-generative core:

  1. India branded generics (≈62–63% of sales after trade generics carve-out). Prescription-driven, field-force-led promotion of branded generics through ~14,000 medical representatives to general practitioners, consulting physicians and specialists. Pricing is partially regulated: BOB Capital Markets estimated that roughly 30% of sales fall under India's National List of Essential Medicines (NLEM) price controls (Q3 FY25 Result Review, 8 February 2025).

  2. India trade generics (historically ~20% of domestic sales). Unbranded or lightly branded generics sold through distributors/retailers rather than promoted to doctors; carved out into wholly owned subsidiary Alkem Wellness Limited effective 1 October 2025. Alkem describes itself as a "leading player in the trade generics segment" (Q4 FY26 presentation).

  3. US generics (≈20% of sales). Oral solids and other generic formulations sold under the Ascend Laboratories front end, supplied from Indian plants (Daman, Baddi) and US API capacity (California). Includes Enzene's US CDMO revenue in reported US figures (Q4 FY26 presentation footnote).

  4. Non-US international (≈12% of sales; fastest-growing). Branded and generic sales in Australia (Pharmacor), Chile/Latin America, Philippines, Kazakhstan, Europe and the Middle East (new Saudi JV and Dubai subsidiaries).

  5. Biosimilars and CDMO (Enzene Biosciences). Biosimilar development and manufacturing in Pune, India and a US CDMO facility; 6–7 biosimilars in the Indian portfolio per BOB Capital Markets (Q1 FY27 Result Review, 14 August 2026).

  6. Medical devices (Alkem MedTech). Orthopaedic implants (Bombay Ortho, renamed Alkem MedTech Ortho; Advita Ortho/Exactech licensing in India) and, since July 2026, structural-heart occluders via Occlutech. Management stated MedTech contributed less than 1% of revenue before Occlutech (Q4 FY26 earnings call, 28 May 2026).

Revenue model and value-chain position

DimensionCharacterization
Product vs. service mixOverwhelmingly product revenue (finished dosage formulations, APIs, nutraceuticals, biosimilars, implants). Service revenue limited to Enzene CDMO (contract development/manufacturing) — not separately disclosed
Subscription / licensingNo subscription revenue; in-licensing and out-licensing deals exist but licensing income not separately disclosed
Value chain positionVertically integrated: API manufacture (Ankleshwar, Mandva, California) → formulation (Baddi, Daman, Sikkim and others) → own distribution and field-force marketing in India; US front end via Ascend
Customer typesIndian physicians (prescribers), chemists/distributors/stockists, hospitals; US wholesalers, retail pharmacy chains, group purchasing organisations; international distributors and tender buyers; CDMO clients (biopharma companies)
End marketsHuman pharmaceuticals (acute and chronic), nutraceuticals/consumer wellness, biologics, orthopaedic and cardiovascular devices
Other operating incomeFY26 "revenue as reported" including other income was INR 152,956 M vs. revenue from operations of INR 147,123 M (StockAnalysis standardized)

Strategy

Stated strategic themes

Synthesizing the FY26 results communication and Q1 FY27 MD commentary, Alkem's stated themes are:

  1. Outperform the Indian market — sustain IPM outperformance through mega-brand building in acute therapies while scaling chronic (FY27 guidance: 100–150 bps outperformance).

  2. Chronic transition — increase chronic contribution, led by anti-diabetics/obesity (semaglutide), derma (Adroit), respiratory and cardiac.

  3. Differentiated international growth — a "differentiated launch pipeline for international markets" (Dr. Vikas Gupta, Q4 FY26 release), with US limited-competition launches (tolvaptan) and accelerated non-US expansion.

  4. Margin discipline — business mix improvement, operating leverage and cost discipline (FY27 EBITDA margin guidance 20–21%).

  5. Build next-phase growth engines — R&D, MedTech and Biotech, "in a disciplined manner" (Sandeep Singh, Q1 FY27 release).

  6. Fix the core — strengthen execution, address operational and regulatory priorities, improve consistency (Q1 FY27 release).

Strategic initiatives (last 24 months)

InitiativeDateDescriptionStatus
Trade generics carve-outDec 2024 → 1 Oct 2025Slump-sale transfer to Alkem Wellness for agility and focus on under-served marketsCompleted
Network rationalizationJan 2025Sale of Indore plant to Rubicon ResearchCompleted; gain INR 142.9 M in FY26
Dermatology expansionFeb–Apr 2025Adroit Biomed acquisition (INR 140 cr)Integrated
MedTech platform — orthopaedicsFeb–Apr 2025Bombay Ortho (INR 147 cr); Advita Ortho licensingIntegrated
Saudi Arabia JVAug 202551:49 subsidiary with local partnerFormation stage
Biosimilar oncology launch2,025Pertuza (pertuzumab) in IndiaLaunched
MedTech platform — cardiovascularFeb–Jul 2026Occlutech 51–55% for EUR 99.4 MCompleted; integration under way
Gulf presenceFeb–Mar 2026Two Dubai subsidiariesIncorporated
GLP-1 entryMar 2026Day-one semaglutide launch; pre-filled syringe at INR 350~11% unit share early
Consumer wellnessApr 2026A to Z Daily launchLaunched
Capacity — Ujjain greenfieldMar 2026Up to INR 533 cr, ~30 acresUnder development
Capacity — Baddi blockAug 2026Up to INR 75 crApproved
US limited-competition launchSep–Oct 2026 (guided)Generic tolvaptan (Jynarque)Launch confirmation pending

Management guidance (FY27)

ParameterGuidanceSource
India growthOutperform IPM by 100–150 bps; double-digit domestic growth targetedQ4 FY26 call
EBITDA margin20–21% (broadly in line with FY26)Q4 FY26 call
TaxShift to new regime, 25% base rate, from April 2026Q4 FY26 call (Sahi)
USTolvaptan launch Sept–Oct 2026, contribution in H2Q4 FY26 call
R&DNot quantified; rising (Q1 FY27 at 4.0% vs 3.5%)Q1 FY27 release

ESG commitments: specific quantified emissions or sustainability targets were not identified in reviewed sources. Cost programmes: no named programme with quantified targets disclosed; cost discipline is cited qualitatively.

Products & Services

Alkem markets 800+ brands in India (Q3 FY23 Press Release). Product-level revenue is not disclosed except for brand-family thresholds. The following catalog is organized by business line and therapy; where a specific attribute is not disclosed, it is marked accordingly.

India — brand-family scale (IQVIA SSA MAT March 2026)

Brand-family size bandCount MAT Mar'21Count MAT Mar'265-year CAGR (%)
Above INR 10 bn0115.2
Above INR 5 bn1112.4
Above INR 1.5 bn51212.4
Above INR 500 M (Q1 FY27 deck shows 17)151611.2

Source: Q4 FY26 and Q1 FY27 Results Presentations. Additional disclosures: 15 brands rank in the IPM Top 300; 36–37 brands (>INR 250 M) rank top-3 in their covered market; 17–20 brand families exceed INR 1 bn (figures differ between the two decks — flagged).

India — flagship brands by therapy

TherapyFlagship brand(s)Molecule / descriptionTarget prescriberStatus / data point
GastrointestinalPAN, PAN-D (PAN family)Pantoprazole; pantoprazole + domperidoneGPs, gastroenterologists, physiciansPAN family crossed INR 10 bn in 2022; second-largest brand family in IPM (Q4 FY26 deck)
Anti-infectivesClavamAmoxicillin + clavulanic acidGPs, paediatricians, ENT, physiciansCrossed INR 6 bn in 2022
Anti-infectivesTaxim, Taxim-OCefotaxime (injectable); cefixime (oral)GPs, physicians, hospitalsFirst anti-infective in India to cross INR 1 bn (2006)
VMN / supplementsA to Z; A to Z DailyMultivitamin-multimineral; everyday wellness variant launched 7 April 2026GPs, consumersA to Z Daily launch per exchange press release (Sharekhan news log)
VMNGemcal, Uprise-D3Calcium/vitamin D3 combinations; vitamin D3Orthopaedics, gynaecologistsBrand names per company historical portfolio; individual sales not disclosed
Pain / analgesicsNot individually disclosedNSAIDs, combinationsOrthopaedics, GPsAlkem pain portfolio grew 1.8x IPM in Q1 FY27
Anti-diabetic / obesitySemaglutide injectable; single-shot pre-filled syringe format from INR 350GLP-1 receptor agonistDiabetologists, endocrinologistsDay-one launch March 2026; ~11% unit share in early IQVIA reports (Q4 FY26 call)
DermatologyGlutone, SkinFay, Racine, FortiSil (Adroit)Skin-lightening/antioxidant, skincare, hair and nail supplementsDermatologists, cosmetologistsAdroit FY24 revenue INR 53.55 cr (BioSpectrum)
RespiratoryPulmocare division portfolioInhalers and respiratory formulationsPulmonologists, chest physiciansDivision launched 2021
Neuro / CNSPortfolio not individually disclosedAntiepileptics, antidepressants etc.Neurologists, psychiatristsOnly key therapy where Alkem under-indexed IPM growth in Q1 FY27 (8.7% vs 12.0%)
Oncology (biosimilar)PertuzaPertuzumab biosimilar (Enzene)OncologistsLaunched 2025 (scanx news log)
Bone health (biosimilar)Teriparatide (Enzene)Recombinant PTH analogueEndocrinologists, orthopaedicsEnzene India portfolio of 6–7 biosimilars (BOB Capital Markets)

India — therapy-wise market position (IQVIA SSA)

TherapyFY26 IPM growth (%)FY26 Alkem growth (%)FY26 market share (%)FY26 IPM rankQ1FY27 Alkem growth (%)Q1FY27 IPM growth (%)Q1FY27 market share (%)Q1FY27 rank
Anti-infectives4.04.413.217.96.913.31
Gastrointestinal5.78.37.9412.210.27.94
VMN9.218.46.7221.415.16.82
Pain / analgesics7.211.65.4320.211.55.63
Anti-diabetic11.514.22.21521.115.52.313
Neuro / CNS9.88.61.6158.712.01.514
Respiratory11.316.22.4816.810.52.48
Dermatology6.111.21.51816.510.31.619

Source: Q4 FY26 Results Presentation (IQVIA SSA MAT Mar'26); Q1 FY27 Results Presentation (IQVIA SSA Qtr Jun'26). Column assignments reconciled against the company's stated count of outperforming therapies.

Trade generics (Alkem Wellness)

Unbranded/low-promotion generic formulations sold to distributors and retail chemists, targeting affordability in under-served markets. Business delivered more than INR 10 bn topline in 2020 (company milestone). Management guided trade generics growth broadly in line with IPM (BOB Capital Markets, Q4 FY25 review); Q1 FY27 trade generics growth was "flattish" while branded generics grew ~12% (BOB Capital Markets, Q1 FY27 review). Pricing model: trade discounts to distributors; specifics not publicly disclosed.

US generics (Ascend Laboratories)

AttributeDetail
Portfolio scale192 ANDAs filed, 2 NDAs, 1 BLA; 170 ANDA approvals (incl. 18 tentative) and 2 NDA approvals as of 30 June 2026 (Q1 FY27 presentation)
FY26 activity8 ANDAs and 1 BLA filed; 17 ANDA approvals; 11 product launches (Motilal Oswal, 28 May 2026)
Q1 FY27 activity5 ANDA approvals (1 tentative)
Near-term flagshipGeneric tolvaptan (reference: Jynarque, ADPKD) — USFDA approval received October 2023; management guided launch September–October 2026 as a limited-competition product (Q4 FY26 call). Launch confirmation not found as of 19 October 2026. Context: Lupin launched with 180-day exclusivity in May 2025; Jynarque US sales were ~USD 1.47 bn in CY2024 (Lupin press release)
Historical flagshipGeneric tolvaptan 30 mg (reference: Samsca), launched May 2020 alongside Apotex (OptumRx)
Pricing modelWholesale/GPO contract pricing; not disclosed

Non-US international

Branded and branded-generic formulations in Australia (Pharmacor), Chile and broader Latin America, Philippines, Kazakhstan/CIS, Europe and the Middle East; Q1 FY27 non-US growth of 34.5% was driven by "double-digit growth across key markets" (Q1 FY27 presentation). Product-level detail not publicly disclosed.

Biosimilars and CDMO (Enzene Biosciences)

OfferingDescriptionStatus
India biosimilars6–7 biosimilars including teriparatide and pertuzumab (Pertuza)Marketed in India; portfolio size per BOB Capital Markets (Aug 2026)
US BLA1 BLA filed with USFDA (FY26)Under review (molecule not disclosed in reviewed sources)
CDMO — IndiaBiologics development and manufacturing for third parties at PuneOperational
CDMO — USUS biologics CDMO facility; adds ~INR 600 M of operating expenses (BOB Capital Markets, Q1 FY27 review)Ramp-up; operating deleverage noted by analysts

Medical devices (Alkem MedTech)

OfferingDescriptionOrigin
Hip and knee implantsOrthopaedic joint replacement implants manufactured in IndiaBombay Ortho (acquired April 2025 for INR 147 cr)
Advita Ortho (Exactech) portfolioLicensed orthopaedic implant portfolio for IndiaLicensing agreement 2024–25
Structural-heart occludersDevices for congenital heart disease (septal defect occluders), stroke prevention (left atrial appendage/PFO closure) and heart failure (atrial flow regulation)Occlutech (51–55% from July 2026); CY2025 revenue EUR 49.4 M (unaudited), 15.7% 3-year CAGR; ~85% of revenue from Europe and US

Financial Narrative

Income statement (consolidated)

Source: StockAnalysis.com standardized consolidated income statement (FY22–FY26); FY25–FY26 EPS from Q4 FY26 Results Presentation; FY22–FY24 EPS derived as net income / 119.57 M shares (no change in share count since IPO).

Company-reported (non-standardized) reconciliation items:

Source: Q4 FY26 Results Presentation. FY26 exceptional items: INR 1,130.6 M labour-code gratuity/leave encashment past-service cost, INR 747 M impairment of real-estate investments, partly offset by INR 142.9 M gain on sale of the Indore facility. Discrepancy: company FY25 gross profit (82,003) and EBITDA (25,122) differ from standardized figures (80,391 and 24,619) due to classification; company figures are preferred for analysis. Company-reported FY24 EBITDA margin was 17.7% (Q4 FY25 Press Release).

Margin profile

Revenue CAGR FY22–FY26: 8.4% (derived: (147,123/106,342)^(1/4) − 1). FY23–FY26 CAGR: 8.3%.

Commentary. The five-year record shows two distinct regimes. FY22–FY23 was a period of margin compression: FY23 EBITDA margin collapsed to 13.7% (standardized) as US price erosion, elevated API/freight costs and a one-off tax-related item depressed earnings — net income fell 40%. FY24–FY26 has been a margin-rebuild phase under the cost-control programme associated with the September 2023 CEO appointment: company-reported EBITDA margin expanded from 17.7% (FY24) to 19.4% (FY25) to 20.4% (FY26), while gross margin widened from ~60% to 65.4%. Drivers cited by management include favourable API prices, cost-control initiatives, an improving business mix (higher chronic share, lower trade generics weight, non-US growth) and operating leverage (Q4 FY25 and Q4 FY26 press releases). The FY26 inflection in revenue growth (13.5% vs 2.3% in FY25) came from a US recovery (+20.3%) and non-US acceleration (+26.7%), with India also accelerating to 9.7%. Below EBITDA, FY26 net income growth (6.3%) lagged EBITDA growth (19.6%) due to INR 1.75 bn of exceptional charges, higher depreciation (new capacity, acquisitions) and a higher tax charge as SEZ benefits roll off.

Q1 FY27 inflection. Q1 FY27 revenue grew 10.9% to INR 37,402 M and gross margin reached a record 67.9%, but EBITDA margin fell to 20.5% from 21.9% because of higher R&D (INR 1,502 M, 4.0% of revenue), Enzene US CDMO operating costs and employee costs (INR 808.9 cr employee benefits expense). PAT fell 21.7% to INR 5,200 M primarily on higher taxation as the company migrated to India's new corporate tax regime (25% base rate) from April 2026 and Sikkim SEZ benefits expire (Quartr earnings summary; Sahi; BOB Capital Markets). Note: some secondary sources misreported Q1 FY27 PBT (INR 422.85 cr) and EPS (INR 19.77) — these appear to be Q4 FY26 figures; the company presentation shows PBT INR 7,720 M and EPS INR 43.5.

Balance sheet

Sources: FinancialFilings.com (FY26 total assets, equity, CFO, per earnings release of 28 May 2026); FY26 Directors' Report (other equity: consolidated INR 137,961.9 M FY26, INR 119,609.6 M FY25 — column assignment inferred); Q4 FY25 Press Release ("cash and balance" INR 46.2 bn, which may be gross rather than net); Q4 FY26 and Q1 FY27 presentations (net cash). FY22–FY24 balance-sheet line items, gross debt split (short/long term), goodwill and intangibles, and working capital were not publicly disclosed in reviewed sources and are not estimated here.

Commentary. Alkem is structurally net-cash. Net cash rose from INR 54.7 bn (March 2026) to INR 57.6 bn (June 2026) despite the final dividend record date falling in August; the July 2026 Occlutech payment (EUR 99.4 M ≈ INR 1,074 cr) will reduce Q2 FY27 net cash by roughly INR 10.7 bn and add goodwill/intangibles and Occlutech's balance sheet on consolidation. Book value per share is approximately INR 1,156 at FY26 (derived: 138,201/119.57); a Business Standard reference of INR 1,116 likely reflects an earlier reporting date.

Cash flow

Sources: FinancialFilings.com (CFO); BOB Capital Markets Q4 FY25 review (FY26 capex guidance); dividend declarations (interim INR 43 per share, February 2026; final INR 10 per share, record date 7 August 2026, paid from 1 September 2026). Historical OCF, capex and FCF for FY22–FY25 were not publicly disclosed in reviewed sources. FY26 OCF/net income conversion of ~85% (19,630/23,018) suggests working-capital absorption during a year of 13.5% growth. Indicative FY26 FCF, if capex was near guidance, would be ~INR 12–12.6 bn — this is an estimate from guidance, not a disclosed figure.

Commentary. H1 FY25 cash generation of ~INR 12.0 bn (BOB Capital Markets, Q2 FY25 review) and the progression of cash balances from INR 46.2 bn to INR 57.6 bn over five quarters — while paying ~INR 6 bn of annual dividends and funding Adroit and Bombay Ortho (~INR 2.9 bn combined) — demonstrate strong underlying FCF. Capital intensity is rising: Ujjain greenfield (up to INR 533 cr), Baddi block (up to INR 75 cr, August 2026), Enzene US CDMO, and Occlutech.

Ratios

Sources: derived from figures above; ROCE from Q4 FY26 Results Presentation. Current ratio, debt/equity and cash conversion cycle are not publicly disclosed in reviewed sources. ROIC is not disclosed; ROCE is the closest company metric. Screener.in shows ROE 19.6% and ROCE 19.7% on its own (post-tax, different denominator) methodology — not directly comparable.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Revenue

SegmentContentsFY2024 revenue (INR Mn)FY2025 revenue (INR Mn)FY2026 revenue (INR Mn)YoY FY26 (%)% of total FY26

Pharmaceuticals (sole reportable segment)

Branded generics, trade generics, US generics, international formulations, APIs, biosimilars, CDMO, nutraceuticals, medical devices

126,676129,645147,12313.5100.0

Business Lines

Business line (sales, INR Mn)FY2024FY2025FY2026

India business (incl. Adroit and Alkem MedTech from FY26)

84,33789,83798,514

US business (incl. Enzene US CDMO; FY24 derived from 22.3% share)

27,73924,81829,845

Non-US international (FY24 derived from 9.9% share)

12,31513,39216,964

Business line YoY growth (%)

Business line YoY growth (%)FY2024FY2025FY2026

India business

5.46.59.7

US business (FY25 derived)

—-10.520.3

Non-US international

—8.726.7

Business line % of total sales (%)

Business line % of total sales (%)FY2024FY2025FY2026

India business

67.870.267.8

US business

22.319.420.5

Non-US international

9.910.511.7

Revenue by Segment and Segment Margins & Growth (%)

Metric (INR Mn)Q1FY26Q2FY26Q3FY26Q4FY26Q1FY27

Revenue from operations (Q2 derived)

33,71140,01137,36836,03337,402

India sales

22,650——23,24524,978

US sales

6,982——7,6817,439

Non-US sales

3,556——4,5434,785

EBITDA (Q2 derived)

7,3919,2078,2805,1747,661

EBITDA margin (%)

21.923.022.214.420.5

PAT after NCI (Q2 derived)

6,6437,6506,3602,3655,200

Group Entities

EntityRoleOwnership

Alkem Laboratories Ltd

Parent; India branded generics, manufacturing, R&D

Listed

Alkem Wellness Ltd

Trade generics business (from 1 Oct 2025)

Wholly owned

Adroit Biomed Ltd

Dermatology/cosmetology brands

Wholly owned (from 23 Apr 2025)

Alkem MedTech Pvt Ltd

Medical devices holding/operating company

Wholly owned

Alkem MedTech Ortho Pvt Ltd (formerly Bombay Ortho Industries)

Hip and knee implants manufacturing

Wholly owned step-down

Occlutech Holding AG (Switzerland)

Structural-heart occluder devices

51–55% via Alkem MedTech (from July 2026)

Enzene Biosciences Ltd (and US CDMO entity)

Biosimilars, biologics CDMO

—

Ascend Laboratories LLC / ThePharmaNetwork LLC (US)

US generics marketing

Wholly owned

S&B Pharma (US)

API manufacturing, California

—

Pharmacor Pty Ltd (Australia)

Australian generics

Wholly owned

—

Manufacture, import, marketing and distribution in KSA

51% (Abdulaziz Alsheikh 49%)

Alkem Pharmaceuticals Scientific Office FZ-LLC (Dubai)

Scientific office

Wholly owned (incorporated 4 Feb 2026)

Alkem Pharma Trading FZCO (Dubai)

Trading

Wholly owned (incorporated 27 Mar 2026)

Income Statement and Margin Analysis (%)

Metric (INR Mn unless stated)FY2022FY2023FY2024FY2025FY2026

Revenue from operations

106,342115,993126,676129,645147,123

Revenue growth (%)

19.969.079.212.3413.48

Gross profit (standardized)

63,53665,78576,03480,39196,195

Operating income EBIT (standardized)

17,43213,19619,67621,51826,232

EBITDA (standardized)

20,12215,89322,26824,61930,052

Depreciation and amortization

2,6902,6972,5923,1013,821

Interest expense

3098099711,0481,608

Net income attributable to owners

16,4569,84217,95821,65523,018

Net income growth (%)

3.82-40.2082.4720.596.30

EPS basic and diluted (INR; FY22–FY24 derived)

137.682.3150.2181.1192.5

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement

Metric (INR Mn)FY2025FY2026

Gross profit (company)

82,00396,195

EBITDA (company)

25,12230,052

PBT before exceptional items

25,27030,457

Exceptional items

0-1,748

PBT after exceptional items

25,27028,709

PAT after non-controlling interest

21,65523,018

Margin (%)

Margin (%)FY2022FY2023FY2024FY2025FY2026

Gross margin (standardized)

59.756.760.062.065.4

Gross margin (company-reported)

———63.365.4

Operating (EBIT) margin

16.411.415.516.617.8

EBITDA margin (standardized)

18.913.717.619.020.4

EBITDA margin (company-reported)

——17.719.420.4

Net margin

15.58.514.216.715.6

Balance Sheet

Metric (INR Mn)FY2025FY2026Q1FY27

Total assets

—208,730—

Total equity incl. NCI

—143,490—

Equity attributable to owners (derived: share capital + consolidated other equity)

119,849138,201—

Cash and bank balances / net cash

46,20054,74057,640

Share capital

239.1239.1239.1

Cash Flow and Dividends & Capital Returns (INR)

Metric (INR Mn)FY2026

Operating cash flow

19,630

Dividends declared for FY26 (INR 53/share; derived)

6,337

Share buybacks

0

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2025FY2026

ROE (%, derived on average attributable equity)

—17.8

ROA (%, derived on period-end total assets)

—11.0

ROCE pre-tax (%, company; Q1 FY27 deck shows 29.6)

—29.4

Interest coverage (EBIT / interest, x)

20.516.3

Net debt / EBITDA (x; negative = net cash)

—-1.8

Asset turnover (x, derived)

—0.70

Revenue by Region

Region (sales, INR Mn)FY2024FY2025FY2026

India

84,33789,83798,514

United States (FY24 derived)

27,73924,81829,845

Rest of world / non-US international (FY24 derived)

12,31513,39216,964

Total sales (sum)

124,391128,047145,323

Region growth (%)

Region growth (%)FY2024FY2025FY2026

India

5.46.59.7

United States (FY25 derived)

—-10.520.3

Rest of world

—8.726.7

Share Price History

DateNSE price (INR)Source

7 Jan 2026

5,785.60

Business Standard

27 Feb 2026

5,658.75

Business Standard

31 Mar 2026

5,299

Q4 FY26 presentation

24 Apr 2026

5,366

BusinessLine (CEO exit day)

27 May 2026

5,452

BOB Capital Markets

30 Jun 2026

5,570

Q1 FY27 presentation

31 Jul 2026

5,751.50

Value Research

14 Aug 2026

~5300

Multibagg (post-results)

17 Sep 2026

5,193

Anand Rathi

24 Sep 2026

5,337

Angel One

Performance

Value

Source / date

1-year return (%)

-5.3

Anand Rathi, 17 Sep 2026

3-year return (%)

41.1

Anand Rathi, 17 Sep 2026 (Value Research shows 12.9% as of 31 Jul 2026 — methodology/date discrepancy)

52-week high / low (INR)

5933.50 / ~4738.50 (Aug 2026); 5933 / 5052.05 (Sep 2026, per Anand Rathi)

Value Research; Anand Rathi

All-time high (INR)

6,439.90

Anand Rathi

IPO (Dec 2015)

Offer for sale, no fresh issue

Pharma Focus Asia

Valuation Multiples

MultipleAlkemBasis

P/E (TTM)

~27x

Anand Rathi, 17 Sep 2026 (26.96x)

P/B

~4.9x

Anand Rathi

EV/EBITDA (TTM, derived)

~18.6x

Mcap ~INR 62,000 cr less net cash ~INR 5,764 cr; TTM EBITDA ~INR 3,032 cr

EV/Sales (TTM, derived)

~3.7x

TTM revenue ~INR 15,081 cr

Forward P/E

~29x FY27E, ~26x FY28E

MOFSL, 28 May 2026 (at INR 5,452)

Peer median P/E

~38x (Value Research, 31 Jul 2026; Alkem at 21% discount)

Value Research

Analyst Ratings & Targets

BrokerDateRatingTarget (INR)Key view

Motilal Oswal

28 May 2026

Neutral

5,840

28x 12-month forward EPS; export momentum and domestic revival offset by biosimilar costs

BOB Capital Markets

29 May 2026

Sell

4,638

Margins flat in FY27; valuation expensive; FY27E revenue INR 163,093 M, EBITDA INR 32,619 M, adj. PAT INR 22,668 M

BOB Capital Markets

14 Aug 2026

Sell

4,590

Enzene CDMO deleverage; EBITDA margin 19.7% FY27E, 20.8% FY28E

Nomura

May 2026

Not stated

Not stated

FY27 guidance in line to ahead

S&P Global consensus (via INDmoney)

2026—

5557 (average)

Slight upside at the time

Per-Share Data and Returns & Leverage Ratios (%)

ItemFY2026

Interim dividend per share (INR)

43

Final dividend per share (INR)

10

Total dividend per share (INR)

53

Payout ratio (derived, % of PAT)

27.5

Analyst Conclusions

Guidance and consensus

Management guides FY27 India growth 100–150 bps ahead of IPM, EBITDA margin of 20–21%, and an H2 contribution from US tolvaptan. Q1 FY27 delivered 20.5% EBITDA margin and 100 bps IPM outperformance — at the low end on both.

Bull case

  1. Chronic re-rating catalyst: semaglutide's ~11% early unit share, plus anti-diabetic growth of 21.1% in Q1 FY27 (1.4x IPM), can lift chronic mix and margins.

  2. US earnings step-up: a limited-competition tolvaptan launch against a ~USD 1.47 bn reference market could add meaningfully to H2 FY27 US sales, offsetting price erosion.

  3. Optionality funded by net cash: INR 57.6 bn net cash plus a 65–68% gross margin supports MedTech (Occlutech) and biosimilars without equity dilution, at ~27x trailing P/E — a discount to the ~38x peer median.

Bear case

  1. Regulatory escalation: the Daman OAI could become a warning letter or import alert, freezing approvals and impairing US growth (US sales grew only 6.5% in Q1 FY27).

  2. Leadership vacuum: CEO and CFO exits during the largest acquisition integration in company history raise execution risk; the MD has acknowledged execution gaps.

  3. Earnings drag from tax and investment: the 25% tax regime, SEZ expiry, Enzene US CDMO opex and Occlutech amortization could keep EPS flat-to-down in FY27 (Q1 FY27 EPS −21.7%), undermining the multiple.

Catalysts and monitorables (next 12 months)

Catalyst / monitorableExpected timing
Q2 FY27 results (first quarter including Occlutech; tolvaptan launch confirmation)By 14 November 2026
CEO and CFO appointmentsPending
USFDA response to Daman remediation (warning letter vs. re-inspection)FY27
Semaglutide share trajectory and pricingMonthly IQVIA
Occlutech integration and first consolidated MedTech disclosureH2 FY27
US BLA review outcome (Enzene)—
Ujjain and Baddi capacity commissioningFY27–FY28
Further promoter stake salesOngoing risk
FY28 guidanceMay 2027

Analyst verdict

Alkem enters the second half of FY27 as a fundamentally sound franchise wrapped in an unusually busy transition. The core is strong: leadership in anti-infectives, a mega-brand machine that has more than doubled its INR 1.5 bn-plus brand families in five years, record FY26 EBITDA of INR 30.1 bn at a 20.4% margin, a 65–68% gross margin and INR 57.6 bn of net cash. The FY24–FY26 margin rebuild was real and largely structural, rooted in mix improvement, procurement and cost discipline rather than one-offs.

Against that, 2026 has stacked three uncertainties on top of each other. First, governance continuity: the professional CEO left in June and the CFO in September, leaving the promoter-MD to steer the Occlutech integration, a CDMO ramp and a regulatory remediation simultaneously. Second, regulatory: the Daman OAI is the most material quality event for Alkem in several years and directly touches the US business, which had only just recovered. Third, earnings optics: tax normalization will likely flatten FY27 EPS despite double-digit revenue and stable EBITDA, which matters for a stock that trades on earnings multiples.

The investment debate therefore hinges less on Alkem's franchise quality — which is not in question — and more on execution over the next two to three quarters. Successful tolvaptan and semaglutide scaling, a credible CEO appointment and a contained Daman outcome would validate the strategy and justify a multiple closer to large-cap peers, given superior balance-sheet strength. Conversely, a warning letter combined with prolonged leadership vacancy would likely keep the stock range-bound near its 52-week band (~INR 4,700–5,900), as analyst targets spanning INR 4,590 (Sell) to INR 5,840 (Neutral) already suggest. On balance, the evidence supports a neutral stance with positive skew: the downside is cushioned by net cash and a ~27x trailing multiple below the peer median, while the upside requires visible evidence that the 2026 transition is being managed, not merely endured.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenure / key datesBackgroundAgeFY26 compensation

Basudeo Narain (B.N.) Singh

Executive Chairman

Co-founder (1973)

Founder-promoter; led Alkem since inception

Not disclosed in reviewed sources

Not publicly disclosed in reviewed sources (refer FY26 Annual Report remuneration disclosures)

Sandeep Singh

Managing Director; de facto lead executive since CEO exit

Joint MD at IPO (2015); MD thereafter

Promoter family; leads Q1 FY27 investor communication

—

Not publicly disclosed in reviewed sources

Madhurima Singh

Executive Director

Appointed November 2023; re-appointed for five years from 20 December 2026 (board approval 28 May 2026, subject to AGM)

Promoter family; stake rose to 6.18% in March 2025 via transmission from estate of late Dhananjay Kumar Singh

—

Not publicly disclosed in reviewed sources

Rajeev Kher

Independent Director

Appointed October 2024

——

Sitting fees/commission not disclosed in reviewed sources

Kaustav Banerjee

CEO, Alkem MedTech

Senior management since December 2023

Led Occlutech transaction

——

Manish Narang

President – Legal, Company Secretary & Compliance Officer

Signatory on 2025–26 filings

Legal/secretarial

——

Chanakya Misra

Senior Management Personnel

From 18 May 2026

Role not specified in reviewed sources

——

Dr. Shubhadeep Sinha

Senior Management Personnel

From 15 September 2026

25+ years in clinical development, medical affairs, pharmacovigilance, regulatory affairs

——

Sunil Sawant

Senior Management Personnel

From 16 December 2025

Role not specified in reviewed sources

——

Purvi Shah

Head of Investor Relations

Current

IR

——

Chief Executive Officer

Vacant

Dr. Vikas Gupta departed 30 June 2026; global search firms engaged (FilingReader, 1 June 2026)

———

Chief Financial Officer

Vacant / successor not identified in reviewed sources

Nitin Agrawal resigned effective 30 September 2026

Agrawal led MedTech vertical set-up and Adroit, Bombay Ortho, Alkem Wellness and Occlutech deals

——

“—” = not publicly disclosed.

Board & Management Changes

DateChangeContext

15 Sep 2023

Dr. Vikas Gupta appointed CEO (effective 22 Sep 2023)

First professional CEO of the post-IPO era to drive margin turnaround

Jan 2024

CFO transition; Nitin Agrawal named successor to outgoing CFO

MarketScreener news log

Jul 2024

"Change in management" disclosed; Yogesh Kaushal retirement (SMP)

MarketScreener news log

Feb 2025

Sanjay Kumar Dipak appointed to senior management

MarketScreener

30 Sep 2025

Amit Ghare (SMP) steps down

Zonebourse/Medical Dialogues

24 Apr 2026

CEO Dr. Vikas Gupta resigns (effective 30 June 2026); stock fell 2.8% to INR 5,366

BusinessLine via AskFuzz

18 May 2026

Chanakya Misra appointed SMP

MarketScreener

15 Sep 2026

Dr. Shubhadeep Sinha appointed SMP

Investywise (BSE)

24 Sep 2026

CFO Nitin Agrawal resignation disclosed (letter dated 30 July 2026; effective 30 Sep 2026)

Angel One; scanx

Shareholding Trend

Holder category (%)31 Mar 202630 Jun 2026

Promoter and promoter group

51.249.7

Institutions (MF, AIF, FPI, FI/banks)

31.533.1

Non-institutions

17.317.3

Competitive Landscape

Competitors by Segment

Business lineCompetitors

India acute (anti-infectives, GI, pain, VMN)

Abbott India, Mankind Pharma, Cipla, Sun Pharma, Intas (unlisted), Macleods (unlisted), Lupin, Alembic, Aristo (unlisted)

India chronic (diabetes, cardiac, neuro, derma)

Sun Pharma, Torrent Pharma, Lupin, Mankind, Zydus Lifesciences, Glenmark, Intas, Dr. Reddy's

Semaglutide / GLP-1 generics (India)

Multiple launches at patent expiry March 2026 (Sun, Dr.

Trade generics

Mankind (via generics), Intas, regional generic houses

US generics

Lupin, Zydus, Aurobindo, Dr. Reddy's, Sun, Cipla, Teva, Viatris, Apotex

Biosimilars (India)

Biocon Biologics, Intas, Dr. Reddy's, Zydus, Reliance Life Sciences

Structural heart devices

Abbott (Amplatzer), W. L. Gore, Boston Scientific (Watchman), Lifetech Scientific; Occlutech claims #2 in Europe, #3 globally in minimally invasive cardiac implants

Orthopaedic implants (India)

Meril Life Sciences, Zimmer Biomet, Stryker, Smith & Nephew, DePuy Synthes

Peer Comparison FY2025

CompanyRevenue FY25 (INR Cr, approx.)Revenue growth FY25 (%, approx.)EBITDA margin FY25 (%, approx.)R&D % of sales FY25 (approx.)

Alkem Laboratories (FY26 actual)

14,71213.520.44.2

Sun Pharmaceutical

~52,000

~8

~28

~6

Cipla

~27,500

~7

~26

~5

Mankind Pharma

~12,200

~18

~25

~2

Torrent Pharmaceuticals

~11,500

~6

~32

~4

Lupin

~22,700

~13

~23

~8

Zydus Lifesciences

~23,200

~19

~29

~7

Company Snapshot

$1,698.9M

Revenue

21,057

Employees

1973

Founded

Mumbai, India

Headquarters

SWOT Analysis

Strengths

  • Category leadership in acute: #1 in anti-infectives for 15+ years with 13.3% share; top-4 positions in GI, VMN and pain (Q1 FY27 presentation, IQVIA Jun'26).
  • Record profitability: FY26 EBITDA of INR 30,052 M (+19.6%), margin 20.4%, gross margin 65.4% (Q4 FY26 presentation).
  • Net-cash balance sheet: INR 57.64 bn net cash at 30 June 2026, enabling self-funded M&A (Q1 FY27 presentation).
  • Brand-building track record: brand families above INR 1.5 bn rose from 5 to 12 between MAT Mar'21 and Mar'26 at a 12.4% CAGR.
  • Prescription reach: #3 nationally in prescriptions (SMSRC MAT Feb'26) with a 13,500–14,500 field force.
  • High pre-tax ROCE: 29.4% in FY26 (Q4 FY26 presentation).

Weaknesses

  • Chronic sub-scale: 2.3% share/#13 in anti-diabetics, 1.5%/#14 in neuro, 1.6%/#19 in derma (Q1 FY27).
  • Neuro/CNS lag: grew 8.7% vs IPM 12.0% in Q1 FY27 and 8.6% vs 9.8% in FY26.
  • Low R&D intensity: 4.2% of revenue in FY26 vs. ~6–8% at US-oriented peers (peer figures indicative).
  • Earnings volatility from exceptional items and tax: Q4 FY26 PAT −22.7% on INR 1,350 M exceptionals; Q1 FY27 PAT −21.7% on tax.
  • Trade generics drag: flattish trade generics growth held reported India growth to 10.3% vs 13.2% IQVIA growth in Q1 FY27 (BOB Capital Markets).
  • Cash conversion: FY26 OCF of INR 19.63 bn ≈ 85% of PAT.

Opportunities

  • GLP-1 obesity/diabetes market: ~11% unit share of semaglutide within ~60 days of launch; pre-filled syringe format from INR 350 (Q4 FY26 call; scanx).
  • US tolvaptan (Jynarque generic): reference product ~USD 1.47 bn US sales (CY2024); limited competition; launch guided Sept–Oct 2026.
  • Structural-heart devices: Occlutech (EUR 49.4 M revenue, 15.7% CAGR, ~85% from Europe/US) provides a platform for India and emerging-market cross-selling.
  • Non-US international: +34.5% in Q1 FY27; Saudi JV and Dubai subsidiaries extend Gulf reach.
  • Biosimilars/CDMO: first US BLA filed (FY26); Enzene US CDMO capacity.
  • Capacity-led growth: Ujjain greenfield (INR 533 cr) and Baddi expansion (INR 75 cr).

Threats

  • USFDA OAI at Daman (August 2026) — risk of warning letter or import alert; may delay approvals from that site.
  • Leadership vacuum: CEO exit (30 June 2026) and CFO exit (30 September 2026) during integration and remediation.
  • Tax normalization: SEZ benefit expiry in FY27 (BOB Capital Markets); Q1 FY27 effective tax ~33% (derived).
  • GLP-1 price war: numerous Indian generic semaglutide entrants at patent expiry.
  • Price controls: ~30% of portfolio under NLEM (BOB Capital Markets).
  • Promoter selling overhang: promoter stake fell from ~56.4% (June 2024) to 49.7% (June 2026) through successive block sales.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
16 Apr 2025Bombay Ortho acquisition completedMedTech manufacturing capability
23 Apr 2025Adroit Biomed acquisition completedDerma portfolio expansion
29–30 May 2025FY25 results: revenue INR 129,645 M (+2.3%), EBITDA margin 19.4% (+170 bps); IPM underperformance (6.8% vs 7.7%)Margin up, growth weak
4 Jun 2025Promoter Jayanti Sinha sells 1.42% (INR 828.7 cr)Overhang; stock −2.5%
Jul 2025Stock hits 52-week low of ~INR 4,716Sentiment trough
12 Jul 2025Board retirements effectiveBoard refresh
12 Aug 2025Q1 FY26: revenue +11%, PAT +21.8% to INR 6,643 M; India +12.0%Growth re-acceleration
12 Aug 2025Saudi JV SHA signedMiddle East entry
Sep 2025California API site USFDA inspection (EIR Oct 2025)Clean outcome
26 Sep 2025BTA signed; trade generics to Alkem Wellness from 1 Oct 2025Structural reorganization
30 Sep 2025SMP Amit Ghare exitsManagement churn
2025GST demand of ~INR 3.37 cr; company to contestMinor legal
2025Pertuza (pertuzumab biosimilar) launchedOncology biosimilars
13 Nov 2025Q2 FY26: record revenue ~INR 4,001 cr (+17%)Peak quarter
16 Dec 2025Sunil Sawant appointed SMP—
13 Feb 2026Q3 FY26: revenue INR 37,368 M (+10.7%), PAT INR 6,360 M (missed estimates); interim dividend INR 43; Occlutech binding offerStock −8% on the day
4 Feb & 27 Mar 2026Dubai subsidiaries incorporatedGulf expansion
Mar 2026EU GMP certificates for Daman (Malta) and Baddi (Germany)European market access
Mar 2026Semaglutide day-one launch in IndiaChronic/obesity entry
19 Mar 2026Ujjain greenfield plant approved (up to INR 533 cr)Capacity
7 Apr 2026A to Z Daily launchedConsumer wellness
13–17 Apr 2026 & 20 Apr–1 May 2026USFDA inspections; Daman Form 483 with 7 observations (disclosed 2 May)Regulatory risk
Apr 2026Taloja BE centre inspected — no observationsPositive
24 Apr 2026CEO Dr. Vikas Gupta resigns (effective 30 Jun)Leadership risk
18 May 2026Chanakya Misra appointed SMP—
28 May 2026FY26 results: record EBITDA INR 30,052 M; final dividend INR 10; FY27 guidanceRecord year
28–29 May 2026Broker reactions: MOFSL Neutral (TP INR 5,840); BOBCAPS Sell (TP INR 4,638); Nomura notes guidance in line/aheadMixed street
1 Jun 2026Earnings call transcript filed; global headhunters engaged for CEOSuccession
30 Jun 2026CEO departure effectiveMD leads
Jul 2026Occlutech acquisition completedLargest deal
30 Jul 2026CFO Nitin Agrawal submits resignation to Chairman(Disclosed 24 Sep)
7–8 Aug 2026USFDA classifies Daman as OAIMaterial regulatory event
14 Aug 2026Q1 FY27: revenue +10.9%, EBITDA +3.7%, PAT −21.7%; Baddi block (INR 75 cr) approved; stock −2.7% to ~INR 5,300Profit miss on tax/costs
14 Aug 2026BOBCAPS reiterates Sell (TP INR 4,590)Bearish coverage
27 Aug 202652nd AGMRe-appointment of Madhurima Singh
1 Sep 2026Final dividend (INR 10) paid—
15 Sep 2026Dr. Shubhadeep Sinha appointed SMP (clinical/regulatory)Strengthens regulatory/medical bench
24 Sep 2026CFO resignation disclosed (effective 30 Sep)Second C-suite exit
7 Oct 2026Meeting with HDFC Mutual FundInvestor engagement
Sep–Oct 2026Guided window for US tolvaptan launchLaunch not yet confirmed in reviewed sources

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Revenue by Segment (FY2024–FY2026): India business (incl. Adroit and Alkem MedTech from FY26) rose from INR 84,337 Mn in FY2024 to INR 98,514 Mn in FY2026.
Alkem Laboratories Limited — Revenue by Segment (FY2024–FY2026)
Series (INR Mn)FY2024FY2025FY2026
India business (incl. Adroit and Alkem MedTech from FY26)84,33789,83798,514
US business (incl. Enzene US CDMO; FY24 from 22.3% share)27,73924,81829,845

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.